| gap-pubmed-20260410- | Which of the myriad proteins and pathways are the primary contributors to neuron | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does PGC-1α loss in PV+ interneurons contribute to circuit dysfunction in ne | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuropsychiatric-disorders |
| gap-pubmed-20260410- | What determines the developmental timing of when PV+ interneurons become respons | open | 0.77 | 0.00 | 2026-04-10 | 0 | | developmental-neurobiology |
| gap-pubmed-20260410- | How does neuronal activity specifically trigger PGC-1α expression in PV+ interne | open | 0.84 | 0.00 | 2026-04-10 | 0 | | developmental-neurobiology |
| gap-pubmed-20260410- | What are the genuine microtubule stabilizers that tau outcompetes in axons? | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do microtubule-stabilizing drugs fail therapeutically if tau dissociation de | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do the abundant stable and labile microtubule fractions functionally interac | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms determine the stability differences between microtubul | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Are tau-MAP6 interactions disrupted in tauopathies and other neurodegenerative d | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do tau and MAP6 spatially segregate on individual microtubules during axonal | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie tau and MAP6's antagonistic effects on microt | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Should microtubule-stabilizing drugs be reconsidered as therapeutic targets for | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do in vitro and non-neuronal cell studies show tau as a microtubule stabiliz | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does tau enable axonal microtubules to have long labile domains while outcom | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do tau and MAP6 balance morphological stability with plasticity beyond micro | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuronal-development |
| gap-pubmed-20260410- | What molecular mechanisms determine tau vs MAP6 segregation patterns on individu | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neuronal-development |
| gap-debate-20260410- | How do different GBA mutation types respond to TFEB activation in patient-derive | open | 0.85 | 0.00 | 2026-04-10 | 0 | | precision-medicine |
| gap-debate-20260410- | What are the long-term toxicity effects of sustained TFEB overactivation in neur | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurotoxicology |
| gap-debate-20260410- | Which specific GBA mutations retain sufficient residual enzyme function to benef | open | 0.75 | 0.00 | 2026-04-10 | 0 | | precision-medicine |
| gap-debate-20260410- | Can enhanced autophagy paradoxically increase α-synuclein aggregation when clear | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What are the long-term safety consequences of sustained TFEB overactivation in n | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurotoxicology |
| gap-debate-20260410- | Does TFEB activation directly restore mutant GBA enzyme activity or only enhance | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Do astrocyte reactivity subtypes exhibit region-specific differences that affect | resolved | 0.71 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What paracrine factors mediate ARAP3-dependent microglial-astrocyte crosstalk an | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | How do bioenergetic checkpoints (ATP/ADP ratios) mechanistically control astrocy | open | 0.78 | 0.00 | 2026-04-10 | 0 | | cellular-metabolism |
| gap-debate-20260410- | What are the optimal temporal windows and biomarkers for switching between Nrf2 | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can astrocyte subtype transitions be reliably controlled or are they stochastic | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Which paracrine factors mediate ARAP3-dependent microglial-astrocyte cross-talk | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroimmunology |
| gap-debate-20260410- | Do bioenergetic checkpoints (ATP/ADP ratios) causally control astrocyte subtype | open | 0.78 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | What is the optimal temporal window for switching between Nrf2 activation and mT | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What biomarkers can distinguish pathological vs protective TREM2+ microglial pop | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | biomarker-development |
| gap-debate-20260410- | How can TREM2 modulators achieve effective brain penetration while maintaining t | open | 0.85 | 0.00 | 2026-04-10 | 0 | | drug-development |
| gap-debate-20260410- | Why do peripheral tissue TREM2 functions fail to predict brain-specific therapeu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | What are the optimal timing windows for TREM2 inhibition vs activation in Alzhei | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How can pathological vs beneficial microglial populations be selectively targete | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What causes poor brain penetration and target engagement of anti-TREM2 antibodie | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | drug-development |
| gap-debate-20260410- | Why do TREM2 therapeutic effects differ dramatically between brain and periphera | open | 0.85 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | What are the optimal temporal windows for TREM2 inhibition vs activation in Alzh | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What is the therapeutic window between selective tau vesicle penetration and non | open | 0.75 | 0.00 | 2026-04-10 | 0 | | pharmacology |
| gap-debate-20260410- | Can nanobodies achieve blood-brain barrier penetration while maintaining tau-bin | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | drug-delivery |
| gap-debate-20260410- | What membrane curvature changes are specifically induced by tau aggregation vers | open | 0.80 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Does tau aggregation specifically cause PS externalization in vesicles independe | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What safety margins exist for membrane-disrupting nanobodies between therapeutic | open | 0.75 | 0.00 | 2026-04-10 | 0 | | pharmacology |
| gap-debate-20260410- | Can nanobodies achieve CNS penetration while maintaining membrane-disrupting act | open | 0.85 | 0.00 | 2026-04-10 | 0 | | drug-delivery |
| gap-debate-20260410- | What membrane curvature changes occur specifically in tau-containing vesicles an | open | 0.80 | 0.00 | 2026-04-10 | 0 | | membrane-biology |
| gap-debate-20260410- | Does tau aggregation specifically cause PS externalization in living cells versu | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What experimental approaches can validate druggability of tau epitopes in pathol | open | 0.80 | 0.00 | 2026-04-10 | 0 | | drug-discovery |
| gap-debate-20260410- | How can therapeutic hypotheses be systematically evaluated without comprehensive | open | 0.70 | 0.00 | 2026-04-10 | 0 | | research-methodology |
| gap-debate-20260410- | What structural differences between physiological and pathological tau enable se | open | 0.85 | 0.00 | 2026-04-10 | 0 | | structural-biology |
| gap-debate-20260410- | Which specific post-translational modifications create druggable epitopes unique | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |